Skip to main content
. 2019 Nov 10;11(1):62–71. doi: 10.1111/1759-7714.13229

Figure 2.

Figure 2

Kaplan‐Meier curves for (a) progression‐free survival, (b) overall survival in the IP arm, and (c) progression‐free survival and (d) overall survival in the EP arm according to GNRI. EP, etoposide/cisplatin; GNRI, Geriatric Nutritional Risk Index; IP, irinotecan/cisplatin. (a, b) (Inline graphic) GNRI > 98 (n = 63), (Inline graphic) GNRI 92–98 (n = 47) and (Inline graphic) GNRI < 92 (n = 60). (c, d) (Inline graphic) GNRI > 98 (n = 70), (Inline graphic) GNRI 92–98 (n = 48) and (Inline graphic) GNRI < 92 (n = 64).